Abstract：【Objective】 To investigate the bone status, influencing factors associated with bone mass, and bone metabolism markers during bone mass changes in patients with primary Sjogren syndrome (pSS). 【Methods】 A total of 55 patients with pSS were selected as the observation group and 50 healthy volunteers were recruited as the control group. The bone mineral density (BMD) of lumbar vertebrae and femoral neck and the bone metabolic markers such as type Ⅰ collagen C-terminal peptide cross-linking (CTX),type Ⅰ procollagen N-terminal propeptide (PINP) and osteocalcin (OC) of the two groups were compared. The correlations of bone metabolic markers with age, duration of disease, body mass index, erythrocyte sedimentation rate(ESR), C-reactive protein(CRP), complement (C3,C4 and C1q) and hormone usage were analyzed. The relationship between BMD and bone metabolism markers in patients with pSS was evaluated as well. 【Results】 The levels of BMD, PINP and OC of lumbar vertebrae and femoral neck in pSS group were lower than those in the control group, while the level of CTX in pSS group was higher than that in control group (P<0.05). The BMD of lumbar vertebrae and femoral neck in pSS group were negatively correlated with age and C1q; and the BMD of lumbar vertebrae was also negatively correlated with hormone usage (P<0.05).The level of CTX in pSS group was negatively correlated with C4 ( P<0.05) and positively correlated with hormone usage (P<0.05).The levels of PINP and OC in patients with pSS were negatively correlated with the levels of CRP and hormone usage, while the level of OC was positively correlated with C4 level (P<0.05). The level of CTX in pSS patients with osteopenia group and osteoporosis subgroup was higher than that in pSS subgroup with normal bone mass; and the levels of PINP and OC in osteoporosis subgroup were lower than those in normal bone mass subgroup. Compared to the control group, the levels of PINP and OC in normal bone mass subgroup of pSS were lower; and the difference was statistically significant (P<0.05).【Conclusion】 Patients with pSS have abnormal BMD and bone metabolism which are correlated with disease activity and hormone usage. The bone metabolic markers can evaluate the status of bone mass in pSS patients.
[1] 王晓婷,李冰.原发性干燥综合征肾损伤的研究进展[J].中国中西医结合肾病杂志,2018,19(5):469-470. [2] 徐艳,臧银善,高玲,等.原发性干燥综合征合并肺受累高分辨CT特点及相关危险因素探讨[J].风湿病与关节炎,2019,8(9):39-43. [3] Dubrovsky AM, Lim MJ, Lane NE. Osteoporosis in rheumatic diseases: anti-rheumatic drugs and the skeleton[J].Calcified Tissue Int,2018, 102(5): 607-618. [4] Pasoto SG, Augusto KL, Alvarenga JC, et al. Cortical bone density and thickness alterations by high-resolution peripheral quantitative computed tomography: association with vertebral fractures in primary Sjogren's syndrome[J].Rheumatology (Oxford),2016, 55(12): 2200-2211. [5] Both T, Zillikens MC, Hoorn EJ, et al. Bone mineral density in Sjogren Syndrome patients with and without distal renal tubular acidosis[J].Calcif Tissue Int,2016, 98(6): 573-579. [6] 李万菊,丁小雪,蒲卉明.系统性红斑狼疮糖皮质激素治疗后骨密度变化及干预措施[J].医学临床研究,2015,32(3):546-548. [7] 鲁芙爱,赵思萌,刘媛,等.系统性红斑狼疮患者髋部骨密度特点分析及与疾病活动度的关系[J].中国骨质疏松杂志,2019,25(12):1725-1729. [8] 鲁志科,孙榕.老年骨质疏松合并高血压患者骨密度及骨代谢标志物的临床研究[J].医学临床研究,2017,34(11):2200-2202. [9] 史清梅,张成磊,孟繁君,等.血清补体C1q与SLE疾病活动的相关性及其在狼疮肾炎诊断中的价值研究[J].宁夏医学杂志,2018,40(2):127-129. [10] Braun A, Sis J, Max R, et al. Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases[J].Scand J Rheumatol,2007, 36(4): 291-298. [11] Eastell R, Szulc P. Use of bone turnover markers in postmenopausal osteoporosis[J].Lancet Diabetes Endocrinol,2017, 5(11): 908-923. [12] Lee KE, Kang JH, Yim YR, et al. The significance of ectopic germinal centers in the minor salivary gland of patients with Sjogren's Syndrome[J].J Korean Med Sci,2016, 31(2): 190-195. [13] 李雅,张丰春.原发性干燥综合征的病情评估体系[J].中华风湿病学杂志,2016,20(2):138-140. [14] Adler RA. Glucocorticoid-induced osteoporosis:management challenges in older patients[J].J Clin Densitom,2019, 22(1): 20-24.
2020, Vol. 37 
